One of IDF Europe's main activities is policy and advocacy at the regional and national level.
At regional level, the main targets of IDF Europe are the EU Institutions (European Parliament and European Commission), the Council of Europe and the World Health Organization European Region.
At national level, the Federation acts as a bridge for its Members by informing them on the latest policy developments Europe-wide. This way, national members can perform their policy and advocay activities at national level, using regional activities as a reference.
MEPs Mobilising for Diabetes (MMD), the MEP Interest Group on Diabetes, was established in November 2020 and continues the work of the EU Diabetes working group and IDF Europe's other advocacy efforts, such as IMPACT Diabetes. The group aims to represent the interests of people living with diabetes, their relatives and carers, as well as those at risk. Under the auspices of co-chairs MEP Sirpa Pietikäinen and MEP Christel Schaldemose, MMD will work to elevate diabetes on the EU political agenda, promote understanding of the multi-faceted nature of diabetes and dispel common misperceptions.
Through close collaboration with the Commission, Council, and individual Member States (MS), MMD will foster EU action around the following priorities:
Improving diabetes management, care, and risk reduction approaches
Promoting better, more affordable, and uninterrupted access to the required medicines and technologies
Eliminating stigma and discrimination against people living with diabetes
100 years after the discovery of insulin, the European Parliament adopts a landmark diabetes resolution
On the Centenary of the Discovery of Insulin and 10 years after the first European Parliament Motion for Resolution on diabetes, on November 23, 2022, the European Parliament adopted a motion for resolution on Prevention, management and better care of diabetes in the EU on the Occasion of World Diabetes Day. IDF Europe applauds this important step forward towards reversing the rising number of people living with diabetes (PwD), improving the management of diabetes and its complications, and addressing the inequalities and disparities in access to care and treatment in Europe.
If put into action, the resolution has the potential to contribute to better health outcomes for millions of EU citizens living with diabetes, as well as with non-communicable diseases (NCDs) and other conditions. IDF Europe thanks President Roberta Metsola and MEPs Mobilising for Diabetes (MMD) for their salient efforts to gather political support, increase awareness of this life-altering disease and their call for urgency to act.
The resolution has the support of the united diabetes community. We want to thank our partners: European Association for the Study of Diabetes (EASD), European Diabetes Forum (EUDF), European Foundation for the Study of Diabetes (EFSD), Foundation of European Nurses in Diabetes (FEND), International Society for Pediatric and Adolescent Diabetes (ISPAD), Juvenile Diabetes Research Foundation (JDRF), Primary Care Diabetes Europe (PCDE), Société Francophone du Diabète (SFD).
We thank our partners, Air Liquide, Boehringer Ingelheim and Lilly Diabetes for their support to our call for a new European Parliament Diabetes Resolution.
Read more about the rationale for a new Diabetes Resolution here
Video message from Portugal's Minister of Health Dr. Marta Temido
Portugal's Minister of Health, Dr. Marta Temido shared with us the key health priorities of the Portuguese Presidency of the Council of the European Union. She also showed her support for the 'Blueprint for Action on Diabetes in the European Union by 2030' published by MEPs Mobilising for Diabetes, the MEP Interest Group on Diabetes in the European Parliament.
MEPs Mobilising for Diabetes - ‘Blueprint for Action on Diabetes in the European Union by 2030’
The official launch of MMD occurred in February 2021 with the release of the ‘Blueprint for Action on Diabetes in the European Union by 2030’.
Written from the perspective of people living with diabetes, the recommendations in this Blueprint cover the whole spectrum of actions to be implemented to improve their lives in Europe. These recommendations are articulated around three key priorities - reducing the risk of developing Type 2 diabetes and diabetes-related complications, integrating care and enabling access. These pillars are supported by three key enablers - engagement of people living with diabetes, digitalisation and data, and research for actionable insights.